Recombinant DNA Technology Market - 2024-2031

July 2024 | 52 pages | ID: RC0409C7DFE4EN
DataM Intelligence

Abstracts

Recombinant DNA Technology Marketis is growing with a CAGR of 4.80% during the forecast period 2026-2035.

The Recombinant DNA Technology Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Recombinant DNA Technology Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Product Type

• Medical*
• Therapeutic Agent
• Human Protein
• Vaccine
• Non-medical
• Biotech Crops
• Specialty Chemicals
• Other

By Component

• Expression System*
• Mammalian
• Bacteria
• Yeast
• Baculovirus / Insect
• Others
• Cloning Vector

By Application

• Food and Agriculture*
• Health and Disease
• Environment
• Others

By End-User

• Biotechnology and Pharmaceutical Companies*
• Academic and Government Research Institutes
• Others

Regional Analysis for Recombinant DNA Technology Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Recombinant DNA Technology Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Product Type
3.2. Market Snippet by Component
3.3. Market Snippet by Application
3.4. Market Snippet by End-User
3.5. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Technological Advancements
    4.1.1.2. Rising of Biopharmaceutical Industry
    4.1.1.3. XX
  4.1.2. Restraints:
    4.1.2.1. Regulatory, scientific, and ethical challenges
    4.1.2.2. The risk associated with the use of Recombinant DNA Technology
    4.1.2.3. XX
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or a Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY PRODUCT TYPE

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
7.3. Market Attractiveness Index, By Product Type Segment
  7.3.1. Medical*
    7.3.1.1. Introduction
    7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    7.3.1.3. Therapeutic Agent
    7.3.1.4. Human Protein
    7.3.1.5. Vaccine
  7.3.2. Non-medical
    7.3.2.1. Biotech Crops
    7.3.2.2. Specialty Chemicals
    7.3.2.3. Other

8. BY COMPONENT

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
8.3. Market Attractiveness Index, By Component Segment
  8.3.1. Expression System*
    8.3.1.1. Introduction
    8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    8.3.1.3. Mammalian
    8.3.1.4. Bacteria
    8.3.1.5. Yeast
    8.3.1.6. Baculovirus / Insect
    8.3.1.7. Others
  8.3.2. Cloning Vector

9. BY APPLICATION

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.3. Market Attractiveness Index, By Application Segment
  9.3.1. Food and Agriculture*
    9.3.1.1. Introduction
    9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  9.3.2. Health and Disease
  9.3.3. Environment
  9.3.4. Others

10. BY END-USER

10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.3. Market Attractiveness Index, By End-User Segment
  10.3.1. Biotechnology and Pharmaceutical Companies*
    10.3.1.1. Introduction
    10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  10.3.2. Academic and Government Research Institutes
  10.3.3. Others

11. BY REGION

11.1. Introduction
11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. The U.S.
    11.4.7.2. Canada
    11.4.7.3. Mexico
11.5. Europe
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. Germany
    11.5.7.2. The U.K.
    11.5.7.3. France
    11.5.7.4. Italy
    11.5.7.5. Spain
    11.5.7.6. Rest of Europe
11.6. South America
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.6.7.1. Brazil
    11.6.7.2. Argentina
    11.6.7.3. Rest of South America
11.7. Asia Pacific
  11.7.1. Introduction
  11.7.2. Key Region-Specific Dynamics
  11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.7.7.1. China
    11.7.7.2. India
    11.7.7.3. Japan
    11.7.7.4. Australia
    11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
  11.8.1. Introduction
  11.8.2. Key Region-Specific Dynamics
  11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
  11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Monsanto Company*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. F. Hoffmann-La Roche Ltd
13.3. Biogen
13.4. Amgen Inc
13.5. Novartis AG
13.6. Eli Lilly and Company
13.7. GenScript
13.8. Pfizer Inc.
13.9. Novo Nordisk A/S
13.10. Sanofi
13.11. Merck KGaA
13.12. Profacgen
13.13. Biocon
13.14. GlaxoSmithKline plc.
13.15. Cibus
13.16. Horizon Discovery Group plc
13.17. New England Biolabs
13.18. Thermo Fisher Scientific, Inc. (LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us